Evaluation of the efficacy of Olanzapine and Aripiprazole in patients with psychotic disorders
Phase 2
Recruiting
- Conditions
- Psychotic Disorders.
- Registration Number
- IRCT20200430047250N1
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 94
Inclusion Criteria
Diagnosing psychotic disorders through clinical interview and DSM-5 & ICSD-III criteria
Prescribing Aripiprazole or Olanzapine as a treatment strategy for psychotic disorders
Patients aged 18-64 years
Exclusion Criteria
Patients simultaneously taking medications such as sleeping pills and Aripiprazole or Olanzapine (drugs that have high sedative effects)
Patients suffering dependence on or abuse of Aripiprazole or Olanzapine
Patients with multiple chronic physical illnesses such as Diabetes, High Blood Pressure, and Rheumatism
Patients with certain health conditions( preventing them form taking Aripiprazole or Olanzapine )
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measurement of body mass index in psychotic patients treated with olanzapine or aripiprazole. Timepoint: At the beginning of the study and one and two months after starting the drug. Method of measurement: Height and weight scales.;Efficacy of olanzapine and aripiprazole in psychotic patients. Timepoint: At the beginning of the study and one and two months after starting the drug. Method of measurement: PANSS Questionnaire.
- Secondary Outcome Measures
Name Time Method